Clinical Trial Update: A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating Telaglenastat (CB-839) with Palbociclib in solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Solid Tumors

Drugs mentioned

• Palbociclib (palbociclib)
• Telaglenastat (telaglenastat)

Snippet

Sponsor: Calithera Biosciences, Inc | Conditions: Solid Tumors, NSCLC | Phase 1, Phase 2 | Status: COMPLETED